• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用多瑞吉透皮贴剂期间尿液中芬太尼和去甲芬太尼的浓度。

Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.

作者信息

Poklis Alphonse, Backer Ronald

机构信息

Department of Pathology, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298-0165, USA.

出版信息

J Anal Toxicol. 2004 Sep;28(6):422-5. doi: 10.1093/jat/28.6.422.

DOI:10.1093/jat/28.6.422
PMID:15516290
Abstract

A study of the urinary concentration of fentanyl (F) and its major metabolite norfentanyl (NF) in chronic pain patients treated with the Duragesic continuous release transdermal patches is presented. These patches are available in 10, 20, 30, and 40 cm(2) sizes releasing 25, 50, 75, and 100 microg/h F, respectively. F is rapidly and extensively metabolized, with NF as the major metabolite. Five hundred-forty six random urine specimens were collected from chronic pain patients wearing 25, 50, 75, or 100 ug F transdermal patches. Urine specimens were collected from hours after application to several days later after continuous F release. Each specimen was analyzed for F, NF, creatinine, and pH. Additionally, each was screened by enzyme immunoassay for the following: amphetamines, barbiturates, benzodiazepines, cocaine metabolite, methadone, phencyclidine, d-propoxyphene, opiates, and marijuana metabolites. All positive screening results were confirmed by gas chromatography-mass spectrometry (GC-MS). F and NF were isolated from urine by solid-phase extraction then identified and quantified by GC-MS in SIM mode. The LODs and LOQs for F and NF were 3 ng/mL, respectively. The results of F and NF analysis of urine form those wearing 25-microg patches (N = 142) was mean F, 47 ng/mL with a range of 0 to 983 ng/mL, and 97% of the specimens contained < 200 ng/mL and mean NF, 175 ng/mL with a range of 0-980 ng/mL, while 95% of the specimens contained < 400 ng/mL. The results of F and NF analysis of urine form those wearing 50 microg patches (N = 184) was: mean F, 74 ng/mL with a range of 0 to 589 ng/mL, and 92% of the specimens contained < 200 ng/mL and mean NF, 257 ng/mL with a range of 0-2200 ng/mL, and 98% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 75 microg patches (N = 85) was mean F, 107 ng/mL with a range of 0 to 1280 ng/mL, and 98% of the specimens contained < 400 ng/mL and mean NF, 328 ng/mL with a range of 0-5630 ng/mL, and 99% of the specimens contained < 1000 ng/mL. The results of F and NF analysis of urine form those wearing 100 ug patches (N = 135) was mean F, 100 ng/mL with a range of 0 to 1080 ng/mL, while 96% of the specimens contained < 400 ng/mL and mean NF, 373 ng/mL with a range of 0-5730 ng/mL, and 95% of the specimens contained < 1000 ng/mL. The incidence of other drugs detected as a percentage the specimens was opiates, 48%, benzodiazepines, 43%; barbiturates, 3%; methadone, 4%; marijuana metabolite, 3%; and cocaine metabolite, 1%. With the exception of F and/or NF, no other drugs were detected in 25% of the specimens. These data demonstrate the wide variation in concentrations of F and NF in random urine specimens following application of Duragesic patches. However, these values obtained during therapeutic use far exceed concentrations previously reported in fatal poisoning. In general, one may expect to find urine NF concentrations 3-4 times higher than those of F.

摘要

本文介绍了一项关于使用多瑞吉持续释放透皮贴剂治疗的慢性疼痛患者尿液中芬太尼(F)及其主要代谢产物去甲芬太尼(NF)浓度的研究。这些贴剂有10、20、30和40平方厘米四种规格,分别释放25、50、75和100微克/小时的F。F能快速且广泛地代谢,NF是主要代谢产物。从佩戴25、50、75或100微克F透皮贴剂的慢性疼痛患者中收集了546份随机尿液标本。尿液标本在开始持续释放F后的数小时至数天内收集。每份标本都分析了F、NF、肌酐和pH值。此外,每份标本还通过酶免疫法进行以下筛查:苯丙胺、巴比妥类、苯二氮卓类、可卡因代谢物、美沙酮、苯环利定、右旋丙氧芬、阿片类药物和大麻代谢物。所有阳性筛查结果均通过气相色谱 - 质谱联用(GC - MS)进行确认。通过固相萃取从尿液中分离出F和NF,然后在选择离子监测(SIM)模式下用GC - MS进行鉴定和定量。F和NF的检测限(LOD)均为3纳克/毫升。佩戴25微克贴剂患者(N = 142)尿液F和NF分析结果为:F平均47纳克/毫升,范围为0至983纳克/毫升,97%的标本F含量<200纳克/毫升;NF平均175纳克/毫升,范围为0至980纳克/毫升,95%的标本NF含量<400纳克/毫升。佩戴50微克贴剂患者(N = 184)尿液F和NF分析结果为:F平均74纳克/毫升,范围为0至589纳克/毫升,92%的标本F含量<200纳克/毫升;NF平均257纳克/毫升,范围为0至2200纳克/毫升,98%的标本NF含量<1000纳克/毫升。佩戴75微克贴剂患者(N = 85)尿液F和NF分析结果为:F平均107纳克/毫升,范围为0至1280纳克/毫升,98%的标本F含量<400纳克/毫升;NF平均328纳克/毫升,范围为0至5630纳克/毫升,99%的标本NF含量<1000纳克/毫升。佩戴100微克贴剂患者(N = 135)尿液F和NF分析结果为:F平均100纳克/毫升,范围为0至1080纳克/毫升,96%的标本F含量<400纳克/毫升;NF平均373纳克/毫升,范围为0至5730纳克/毫升,95%的标本NF含量<1000纳克/毫升。检测出的其他药物在标本中所占百分比为:阿片类药物48%,苯二氮卓类43%;巴比妥类3%;美沙酮4%;大麻代谢物3%;可卡因代谢物1%。除F和/或NF外,25%的标本未检测到其他药物。这些数据表明,使用多瑞吉贴剂后随机尿液标本中F和NF浓度存在很大差异。然而,这些治疗期间获得的值远远超过先前致命中毒报告中的浓度。一般来说,尿液中NF浓度可能比F高3 - 4倍。

相似文献

1
Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.使用多瑞吉透皮贴剂期间尿液中芬太尼和去甲芬太尼的浓度。
J Anal Toxicol. 2004 Sep;28(6):422-5. doi: 10.1093/jat/28.6.422.
2
LC-MS/MS analysis of fentanyl and norfentanyl in a fatality due to application of multiple Durogesic transdermal therapeutic systems.在因使用多个多瑞吉透皮治疗系统导致死亡的案例中对芬太尼和去甲芬太尼进行液相色谱-串联质谱分析。
Forensic Sci Int. 2007 Jul 4;169(2-3):223-7. doi: 10.1016/j.forsciint.2006.03.018. Epub 2006 May 2.
3
Fentanyl transdermal absorption linked to pharmacokinetic characteristics in patients undergoing palliative care.芬太尼透皮吸收与接受姑息治疗患者的药代动力学特征相关。
J Clin Pharmacol. 2010 Jun;50(6):667-78. doi: 10.1177/0091270009347872. Epub 2010 Jan 23.
4
Fentanyl-Norfentanyl Concentrations During Transdermal Patch Application: LC-MS-MS Urine Analysis.透皮贴剂使用过程中芬太尼 - 去甲芬太尼浓度:液相色谱 - 串联质谱法尿液分析
J Anal Toxicol. 2016 Oct;40(8):595-600. doi: 10.1093/jat/bkw067. Epub 2016 Jul 11.
5
Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases.多瑞吉透皮贴剂:25例尸检中芬太尼的组织分布情况
J Anal Toxicol. 2000 Oct;24(7):627-34. doi: 10.1093/jat/24.7.627.
6
Performance of a Norfentanyl Immunoassay in Specimens with Low Concentrations of Fentanyl and/or Norfentanyl.低浓度芬太尼和/或去甲芬太尼标本中诺芬太尼免疫分析法的性能。
J Appl Lab Med. 2024 Sep 3;9(5):895-904. doi: 10.1093/jalm/jfae036.
7
Monitoring opiate use in substance abuse treatment patients with sweat and urine drug testing.通过汗液和尿液药物检测监测药物滥用治疗患者中的阿片类药物使用情况。
J Anal Toxicol. 2000 Oct;24(7):509-21. doi: 10.1093/jat/24.7.509.
8
Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS.采用液相色谱-串联质谱法测定人血浆中的芬太尼以及人尿液中的芬太尼和去甲芬太尼。
J Pharm Biomed Anal. 2005 Apr 29;37(5):1095-100. doi: 10.1016/j.jpba.2004.09.024.
9
Urine drug testing of chronic pain patients: licit and illicit drug patterns.慢性疼痛患者的尿液药物检测:合法与非法药物模式
J Anal Toxicol. 2008 Oct;32(8):530-43. doi: 10.1093/jat/32.8.530.
10
Fast increase of postmortem fentanyl blood concentrations after transdermal application: A call to careful interpretation.透皮贴剂应用后尸检血芬太尼浓度快速升高:呼吁谨慎解读。
Forensic Sci Int. 2019 Sep;302:109896. doi: 10.1016/j.forsciint.2019.109896. Epub 2019 Jul 26.

引用本文的文献

1
Size-Based Norfentanyl Detection with SWCNT@UiO-MOF Composites.基于尺寸的单壁碳纳米管@UiO-金属有机框架复合材料检测诺芬太尼
ACS Appl Mater Interfaces. 2024 Jan 10;16(1):1361-1369. doi: 10.1021/acsami.3c17503. Epub 2023 Dec 26.
2
A pilot PT scheme for external assessment of laboratory performance in testing synthetic opioid compounds in urine, plasma, and whole blood.一个试点的外部评估实验室性能的方案,用于检测尿液、血浆和全血中的合成阿片化合物。
Forensic Sci Int. 2023 Jun;347:111679. doi: 10.1016/j.forsciint.2023.111679. Epub 2023 Apr 5.
3
Accurate prediction of terahertz spectra of molecular crystals of fentanyl and its analogs.
准确预测芬太尼及其类似物的分子晶体太赫兹光谱。
Sci Rep. 2021 Feb 18;11(1):4062. doi: 10.1038/s41598-021-83536-y.
4
Protracted renal clearance of fentanyl in persons with opioid use disorder.阿片类物质使用障碍者中芬太尼的肾脏清除时间延长。
Drug Alcohol Depend. 2020 Sep 1;214:108147. doi: 10.1016/j.drugalcdep.2020.108147. Epub 2020 Jul 2.
5
Development and Clinical Validation of a Sensitive Lateral Flow Assay for Rapid Urine Fentanyl Screening in the Emergency Department.开发并临床验证一种灵敏的侧向流动分析检测用于急诊快速尿液芬太尼筛查
Clin Chem. 2020 Feb 1;66(2):324-332. doi: 10.1093/clinchem/hvz023.
6
Expected and actual fentanyl exposure among persons seeking opioid withdrawal management.寻求阿片类药物戒断管理的患者中预期和实际芬太尼暴露情况。
J Subst Abuse Treat. 2018 Mar;86:65-69. doi: 10.1016/j.jsat.2018.01.005. Epub 2018 Jan 4.
7
Fentanyl Formulations in the Management of Pain: An Update.芬太尼制剂在疼痛管理中的应用:更新。
Drugs. 2017 May;77(7):747-763. doi: 10.1007/s40265-017-0727-z.
8
Toxicological testing when evaluating fatal cases suspected of acute fentanyl toxicity.在评估疑似急性芬太尼中毒的致命病例时进行毒理学检测。
Forensic Sci Med Pathol. 2016 Sep;12(3):363-5. doi: 10.1007/s12024-016-9789-6. Epub 2016 Jul 7.
9
Quantitative low-volume assay for simultaneous determination of fentanyl, norfentanyl, and minor metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry (LC-MS/MS).液相色谱-串联质谱法(LC-MS/MS)同时测定人血浆和尿液中芬太尼、去甲芬太尼及微量代谢物的定量低体积分析方法。
Int J Legal Med. 2014 Sep;128(5):771-8. doi: 10.1007/s00414-014-1040-y. Epub 2014 Jul 6.
10
Assisted suicide by fentanyl intoxication due to excessive transdermal application.因经皮过量使用芬太尼导致芬太尼中毒而实施的协助自杀。
Int J Legal Med. 2014 Nov;128(6):949-56. doi: 10.1007/s00414-014-0982-4. Epub 2014 Feb 28.